Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?
Table 3
The evolution of frequency in the course of the study.
Variable
Baseline n (%) [B]
Week 1 n (%) [W1]
Week 6 n (%) [W6]
Statistical analyses inside each group
Control group (n=110) C
5 (4.5)
25 (22.7)
12 (10.9)
B vs.W1, p <0.001 B vs. W6, NS W1 vs. W6, p <0.05
Treatment group 1 (10 mg of solifenacin) (n=114) S
6 (5.3)
22 (19.3)
12 (10.5)
B vs.W1, p <0.005 B vs. W6, NS W1 vs. W6, NS
Treatment group 2 (50 mg of mirabegron) (n=104) M
6 (5.8)
15 (13.6)
3 (2.9)
B vs.W1, p <0.05 B vs. W6, NS W1 vs. W6, p <0.005
Baseline: C vs. S (NS); C vs. M (NS); S vs. M (NS). Week 1: C vs. S (NS); C vs. M (NS); S vs. M (NS). Week 6: C vs. S (NS); C vs. M (p<0.05); S vs. M (p <0.05).
